Showing results (41-50 of 59) with videos related to
Sort By:
Pageof 6
American Journal of Clinical Oncology|October 22, 2014
Dose-escalated Hypofractionated Intensity-modulated Radiation Therapy With Concurrent Chemotherapy for Inoperable or Unresectable Non-Small Cell Lung CancerJulian O Kim, Karen P Chu, Alysa Fairchild, et al.Clinical Lung Cancer|February 14, 2016
Phase II Study of Concurrent Pemetrexed, Cisplatin, and Radiation Therapy for Stage IIIA/B Unresectable Non-Small Cell Lung CancerAnthony Brade, Robert MacRae, Scott A Laurie, et al.Cancer Causes & Control : CCC|March 18, 2022
Lifestyle factors and lung cancer risk among never smokers in the Canadian Partnership for Tomorrow's Health (CanPath)Rachel A Murphy, Maryam Darvishian, Jia Qi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2022
COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung CancerRoy S Herbst, Margarita Majem, Fabrice Barlesi, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 19, 2011
Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials GroupScott A Laurie, Ashish Gupta, Quincy Chu, et al.JAMA Network Open|July 15, 2025
Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non-Small Cell Lung Cancer: Update From the COAST Randomized Clinical TrialCharu Aggarwal, Alex Martinez-Marti, Margarita Majem, et al.Therapeutic Advances in Medical Oncology|May 12, 2025
Xevinapant plus avelumab in advanced solid tumours, with a dose expansion in advanced non-small-cell lung cancer: exploratory biomarker, safety and efficacy analyses from an open-label, nonrandomised phase Ib studyGlenwood Goss, Tudor Ciuleanu, Rodryg Ramlau, et al.Targeted Oncology|June 6, 2023
A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid TumorsTodd M Bauer, Kathleen N Moore, Janet S Rader, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 17, 2017
Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung CancerEnriqueta Felip, Fabrice Barlesi, Benjamin Besse, et al.The Lancet. Oncology|March 25, 2015
Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trialLee M Krug, Hedy L Kindler, Hilary Calvert, et al.Pageof 6